{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:20:10Z","timestamp":1791505210883,"version":"4.3.4"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immunotherapy-based regimens have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most disease subtypes remain almost incurable. TG-1801, a bispecific antibody that targets CD47 selectively on CD19+ B-cells, is under clinical evaluation in relapsed\/refractory (R\/R) B-NHL patients either as a single-agent or in combination with ublituximab, a new generation CD20 antibody.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A set of eight B-NHL cell lines and primary samples were cultured <jats:italic>in vitro<\/jats:italic> in the presence of bone marrow-derived stromal cells, M2-polarized primary macrophages, and primary circulating PBMCs as a source of effector cells. Cell response to TG-1801 alone or combined with the U2 regimen associating ublituximab to the PI3K\u03b4 inhibitor umbralisib, was analyzed by proliferation assay, western blot, transcriptomic analysis (qPCR array and RNA sequencing followed by gene set enrichment analysis) and\/or quantification of antibody-dependent cell death (ADCC) and antibody-dependent cell phagocytosis (ADCP). CRISPR-Cas9 gene edition was used to selectively abrogate GPR183 gene expression in B-NHL cells. In vivo, drug efficacy was determined in immunodeficient (NSG mice) or immune-competent (chicken embryo chorioallantoic membrane (CAM)) B-NHL xenograft models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Using a panel of B-NHL co-cultures, we show that TG-1801, by disrupting the CD47-SIRP\u03b1 axis, potentiates anti-CD20-mediated ADCC and ADCP. This led to a remarkable and durable antitumor effect of the triplet therapy composed by TG-1801 and U2 regimen, <jats:italic>in vitro<\/jats:italic>, as well as in mice and CAM xenograft models of B-NHL. Transcriptomic analysis also uncovered the upregulation of the G protein-coupled and inflammatory receptor, GPR183, as a crucial event associated with the efficacy of the triplet combination. Genetic depletion and pharmacological inhibition of GPR183 impaired ADCP initiation, cytoskeleton remodeling and cell migration in 2D and 3D spheroid B-NHL co-cultures, and disrupted macrophage-mediated control of tumor growth in B-NHL CAM xenografts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Altogether, our results support a crucial role for GPR183 in the recognition and elimination of malignant B cells upon concomitant targeting of CD20, CD47 and PI3K\u03b4, and warrant further clinical evaluation of this triplet regimen in B-NHL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1130052","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:44:09Z","timestamp":1682052249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20\/PI3K\u03b4i dual therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Marcelo Lima","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Profit\u00f3s-Pelej\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Carvalho","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Blecua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Reyes-Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Fern\u00e1ndez-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari P.","family":"Miskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Esteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Normant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Rou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1100369","article-title":"Cancer immunotherapy: a treatment for the masses","volume":"305","author":"Blattman","year":"2004","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100825","DOI":"10.1016\/j.currproblcancer.2021.100825","article-title":"Emerging new cell therapies\/immune therapies in b-cell non-hodgkin\u2019s lymphoma","volume":"46","author":"Banerjee","year":"2022","journal-title":"Curr Probl Canc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed b-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv [Internet]"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.09024.x","article-title":"Risk factors and treatment of childhood and adolescent burkitt lymphoma\/leukaemia","volume":"156","author":"Miles","year":"2012","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.21.3707","article-title":"Molecular biology of burkitt\u2019s lymphoma","volume":"18","author":"Hecht","year":"2000","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13020214","article-title":"Immune-checkpoint inhibitors in b-cell lymphoma","volume":"13","author":"Armengol","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1739408","DOI":"10.1080\/19420862.2020.1739408","article-title":"Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors","volume":"12","author":"Hatterer","year":"2020","journal-title":"MAbs [Internet]"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1095","article-title":"Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of b-cell lymphoma and leukemia","volume":"17","author":"Buatois","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-022-00279-w","article-title":"CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a b-cell lymphoma xenograft model","volume":"11","author":"Chauchet","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700323","article-title":"The PI3K\u03b4-selective inhibitor idelalisib minimally interferes with immune effector function mediated by rituximab or obinutuzumab and significantly augments b cell depletion in vivo","volume":"200","author":"Palazzo","year":"2018","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002118","article-title":"Ublituximab and umbralisib in relapsed\/refractory b-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Lunning","year":"2019","journal-title":"Blood [Internet]"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1067","article-title":"Antitumor activity of the novel BTK inhibitor TG-1701 is associated with disruption of ikaros signaling in patients with b-cell non-Hodgkin lymphoma","volume":"27","author":"Ribeiro","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0447-6","article-title":"Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of b-cell non-Hodgkin lymphoma","volume":"10","author":"Balsas","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/15233","article-title":"CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia","volume":"5","author":"Mateo","year":"1999","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-339","article-title":"The chick chorioallantoic membrane as an in vivo xenograft model for burkitt lymphoma","volume":"14","author":"Klingenberg","year":"2014","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.3324\/haematol.2022.281988","article-title":"Interleukin-1 receptor associated kinase 1\/4 and bromodomain and extraterminal inhibitions converge on NF-\u03baB blockade and display synergistic antitumoral activity in activated b-cell subset of diffuse large b-cell lymphoma with MYD88L265P mutation","volume":"106","author":"Dlouhy","year":"2020","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature10226","article-title":"Oxysterols direct b-cell migration through EBI2","volume":"475","author":"Liu","year":"2011","journal-title":"Nat"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nature08226","article-title":"EBV induced molecule-2 mediates b cell segregation between outer and center follicle","volume":"460","author":"Pereira","year":"2009","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800504","article-title":"Characterization of subpopulations of chicken mononuclear phagocytes that express TIM4 and CSF1R","volume":"202","author":"Hu","year":"2019","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2010.23","article-title":"Three-dimensional tissue culture based on magnetic cell levitation","volume":"5","author":"Souza","year":"2010","journal-title":"Nat Nanotechnol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1021\/jm4019355","article-title":"Identification and characterization of small molecule modulators of the Epstein\u2013Barr virus-induced gene 2 (EBI2) receptor","volume":"57","author":"Gessier","year":"2014","journal-title":"J Med Chem"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-208876","article-title":"EBI2 regulates CXCL13-mediated responses by heterodimerization with CXCR5","volume":"26","author":"Barroso","year":"2012","journal-title":"FASEB J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13690","article-title":"Caspase-independent type III programmed cell death in chronic lymphocytic leukemia: the key role of the f-actin cytoskeleton","volume":"94","author":"Barbier","year":"2009","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRP\u03b1\u2013CD47 immune checkpoint blockade in anticancer therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1062192","article-title":"A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells","volume":"7","author":"Piccione","year":"2015","journal-title":"MAbs"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.114.8.1439","article-title":"Phosphoinositide 3-kinase signalling pathways","volume":"114","author":"Cantrell","year":"2001","journal-title":"J Cell Sci [Internet]"},{"key":"B35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nat [Internet]"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature b cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005722","article-title":"Follicular lymphoma and macrophages: impact of approved and novel therapies","volume":"5","author":"Gouni","year":"2021","journal-title":"Blood Adv [Internet]"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.132","article-title":"Inhibiting macrophage PI3K\u03b3 to enhance immunotherapy","volume":"26","author":"Zheng","year":"2016","journal-title":"Cell Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nat [Internet]"},{"key":"B40","doi-asserted-by":"publisher","first-page":"110021","DOI":"10.1016\/j.celrep.2021.110021","article-title":"Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade","volume":"37","author":"Wang","year":"2021","journal-title":"Cell Rep"},{"key":"B41","article-title":"7a, 25-dihydroxycholesterol-mediated activation of EBI2 in immune regulation and diseases [Internet]","volume-title":"Front Pharmacol","author":"Sun","year":"2015"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2555","article-title":"The chemotactic receptor EBI2 regulates the homeostasis, localization and immunological function of splenic dendritic cells","volume":"14","author":"Gatto","year":"2013","journal-title":"Nat Immunol [Internet]"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.01.007","article-title":"B cell localization: regulation by EBI2 and its oxysterol ligand","volume":"34","author":"Gatto","year":"2013","journal-title":"Trends Immunol [Internet]"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2201306","DOI":"10.1183\/13993003.01306-2022","article-title":"GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection","volume":"61","author":"Foo","year":"2022","journal-title":"Eur Respir J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17139","article-title":"Effects of CD20 antibodies and kinase inhibitors on b-cell receptor signalling and survival of chronic lymphocytic leukaemia cells","volume":"192","author":"Cavallini","year":"2021","journal-title":"Br J Haematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2242","article-title":"Lenalidomide, thalidomide, and pomalidomide reactivate the Epstein-Barr virus lytic cycle through phosphoinositide 3-kinase signaling and ikaros expression","volume":"22","author":"Jones","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1130052\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:44:15Z","timestamp":1682052255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1130052\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2023.1130052"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1130052","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1130052"}}